December 8, 2020Open Access
View Full PaperClinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis
Key Points
- To evaluate the clinical outcomes based on albuminuria status in diabetes patients receiving dulaglutide or insulin glargine.
- Analyzed clinical outcomes from the AWARD-7 trial focusing on 1.5 mg dulaglutide weekly compared to daily insulin glargine.
- Highlighted subgroup analysis for participants with macroalbuminuria.
- Examined the rates of eGFR decline and ESKD.
- 1.5 mg dulaglutide treatment was linked to a ≥40% reduction in the risk of eGFR decline or ESKD compared to insulin glargine.
- The macroalbuminuria subgroup showed particularly favorable outcomes from dulaglutide treatment.
Abstract
Treatment with 1.5 mg DU weekly was associated with a clinically relevant risk reduction of ≥40% eGFR decline or ESKD compared with IG daily, particularly in the macroalbuminuria subgroup of participants with T2DM and moderate-to-severe CKD.